Challenging the equipotency calculation for transdermal buprenorphine: Four case studies

International Journal of Clinical Practice

Volumn 62, Issue 1, 2008, Pages 152-156

  Likar, R ^a   Krainer, B ^a   Sittl, R ^b  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMLODIPINE; ARTHROTEC; BUPRENORPHINE; CALCIUM CARBONATE; CARBAMAZEPINE; COLECALCIFEROL; DICLOFENAC; DIPYRONE; FENTANYL; FLUINDOSTATIN; GABAPENTIN; HYDROMORPHONE; LACTULOSE; LANSOPRAZOLE; LEVOTHYROXINE; LISINOPRIL; LORMETAZEPAM; MEFENAMIC ACID; METOPROLOL; MORPHINE; OPIATE; PAROXETINE; PREGABALIN; TIZANIDINE; TRAMADOL; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG;

ACUPUNCTURE; ADULT; AGED; ANALGESIA; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; MALE; MORNING DOSAGE; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; SACRUM; SPINAL PAIN;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN;

EID: 37349055714     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01531.x     Document Type: Article

References (25)

1. Zech DF, Grond S, Lynch J et al. Validation of World Health Organisation Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995 63 : 65 76.
2. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 1991 42 : 228 39.
3. Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs 2001 5 : 163 5.
4. Vallerand AH. The use of long-acting opioids in chronic pain management. Nurs Clin North Am 2003 38 : 435 45.
5. Ahmedzai S, Brooks D, for the TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. Pain Symptom Manage 1997 13 : 254 61.
6. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006 32 : 304 15.
7. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 353 : 1695 700.
8. Quigley C. Opioid switching to improve pain relief and drug tolerability (Cochrane Review). In : The Cochrane Library, issue 4. Chichester, UK : John Wiley & Sons, 2004.
9. Pereira J, Lawlor P, Vigano A et al. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001 22 : 672 87.
10. Lewis JW, Husbands SM. The orvinols and related opioids: high affinity ligands with diverse efficacy profiles. Curr Pharm Des 2004 10 : 717 32.
11. Grünenthal GmbH. Transtec® Summary of Product Characteristics. Aachen, Germany : Grünenthal GmbH, 2003.
12. Sturm C, Sifferman A, Frey OR. Transdermal therapeutic systems in pain management: practical hints for application. Krankenhauspharmazie 2003 24 : 7 14.
13. Sittl R, Likar R, Poulsen Nautrup B. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005 27 : 225 37.
14. Dellemijn PLI, Vanneste JAL. Randomised, double-blind, active-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997 349 : 753 8.
15. Harati Y, Gooch C, Swenson M et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998 50 : 1842 6.
16. Sindrup SH, Andersen G, Madsen C et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999 83 : 85 90.
17. Rowbotham MC, Twilling L, Davies PS et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003 348 : 1223 32.
18. McCormack K. Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids. Part II: moving basic science towards a new pharmacotherapy. Pain Rev 1999 6 : 99 131.
19. Gammaitoni A, Fine P, Alvarez N et al. Clinical application of opioid equianalgesic data. Clin J Pain 2003 19 : 286 97.
20. Mercadante S. Opioid rotation for cancer pain. Rationale and clinical aspects. Cancer 1999 86 : 1856 66.
21. Rothman RB, Ni Q, Xu H. Buprenorphine: a review of the binding literature. In : Cowan A, Lewis AJ, eds. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York, NY : Wiley-Liss, 1995 : 19 29.
22. + channel-acting drugs. Br J Pharmacol 1995 114 : 1296 302.
23. McLaughlin CR, Dewey RL. A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. Pharmacol Biochem Behav 1994 49 : 1017 23.
24. Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 2005 100 : 781 5.
25. Mercadante S, Portenoy RK. Opioid poorly responsive cancer pain. Part 1. Clinical considerations. J Pain Symptom Manage 2001 21 : 144 50.